DailyStocks Stock Article Search

https://seekingalpha.com/news/4118066-tevogen-bio-files-to-sell-425m-shares-plans-to-offer-shares-and-warrants-for-holders?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news Jun 21, 2024 - Tevogen Bio disclosed in an SEC filing on Friday after the bell a prospectus to offer and sell 42.5 million shares of common stock. 0

https://www.zacks.com/stock/news/2291535/wall-street-analysts-predict-a-90-53-upside-in-theravance-bio-tbph-here-s-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2291535 Jun 21, 2024 - The mean of analysts' price targets for Theravance Bio (TBPH) points to a 90.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. 0

https://seekingalpha.com/news/4117110-mustang-bio-stock-soars-after-closing-477-percent-higher-in-prior-session?source=feed_sector_healthcare Jun 18, 2024 - Mustang Bio (MBIO) shares were up 45% Tuesday after closing 477% higher Monday following positive data for the company’s blood cancer drug MB-106. Read more here. 0

https://seekingalpha.com/article/4699867-bio-key-international-inc-bkyi-q1-2024-earnings-call-transcript?source=feed_sector_transcripts Jun 18, 2024 - BIO-key International, Inc. (NASDAQ:NASDAQ:BKYI) Q1 2024 Earnings Conference Call June 18, 2024 10:00 AM ETCorporate ParticipantsBill Jones - Investor... 0

https://www.zacks.com/stock/news/2289743/passage-bio-pasg-loses-22-9-in-4-weeks-here-s-why-a-trend-reversal-may-be-around-the-corner?cid=CS-ZC-FT-tale_of_the_tape|rsi-2289743 Jun 18, 2024 - The heavy selling pressure might have exhausted for Passage Bio (PASG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. 0

https://seekingalpha.com/news/4116753-mustang-bio-stock-rockets-on-blood-cancer-drug-study?source=feed_sector_healthcare Jun 17, 2024 - Mustang Bio (MBIO) stock rocketed 580% Monday after the company reported positive data from a Phase 1/2 trial for its CAR-T cell therapy MB-106. Read more here. 0

https://www.rttnews.com/story.aspx?Id=3454735 Jun 17, 2024 - Mustang Bio, Inc. (MBIO) shares were surging more than 207 percent in the pre-market activity on the Nasdaq after the clinical-stage biopharmaceutical company announced Monday favorable efficacy and safety data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T-cell therapy in patients with Waldenstrom macroglobulinemia or WM, a rare form of blood cancer. 0

https://seekingalpha.com/news/4116379-cabaletta-bio-stock-slips-cell-therapy-data?source=feed_sector_healthcare Jun 14, 2024 - Cabaletta Bio (CABA) stock falls after the company posted initial Phase 1/2 trial results for its lead asset CABA-201 in patients with immune disorders. Read more here. 0

https://www.zacks.com/stock/news/2288483/bears-are-losing-control-over-palisade-bio-pali-here-s-why-it-s-a-buy-now?cid=CS-ZC-FT-tale_of_the_tape|hammer_chart_pattern_(ta)-2288483 Jun 14, 2024 - Palisade Bio (PALI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. 0

https://seekingalpha.com/news/4115884-barinthus-bio-cuts-staff-amid-pipeline-shakeup?source=feed_sector_healthcare Jun 13, 2024 - Barinthus Biotherapeutics (BRNS) is reducing its workforce to focus on experimental therapies for chronic hepatitis B and celiac disease. Read more here. 0